So patients who are started on renzacateib, uh, the primary objective of treatment is to reduce the risk of exacerbation, but there may be other benefits as well. Um, I have my own personal experience, which is one of the first patients that I started on renzacateib, uh, had a really striking symptom response. This is a drug that works in the bone marrow, so it doesn't work straight away. Uh, the, the reduction in neutrophil serum proteases happens over about 2 to 4 weeks. Uh, and so my, my anecdotal experience was one of these first patients that I started on active treatment, um, within 2 weeks they reported to me that their coughing was less and that they'd noticed. That their sputum production was was reducing, which is very much consistent with the biology of the drug. The patient had no way of knowing, the, the patient was not a neutrophil biologist, they didn't know that they were meant to have an effect, at 2 weeks, it was remarkable that it happened. At exactly the right time, uh, the, the, the biology would be expected to kick in, and so I think we will notice that patients have that kind of response, if the drug is working, uh, as, uh, as we get more experience with the drug. In terms of evaluating the overall response, because we're looking for an exacerbation benefit, the most important thing will be actually to monitor the patients over 1 year and ask, have I reduced the number of exacerbations that they've had over that year. So if they had 3 last year and now on renzicib they've had 1, we'd say this is a patient who's having a response, much as we currently do with other therapies like Macrolide or inhaled antibiotic. Um, so those are the things that we should be looking for, and I think these patients should also be getting regular spirometry to look at whether we've managed to put them onto a good track in terms of prevention of disease progression. Um, not every patient will notice a symptom benefit, we know that from the clinical trials, and so that's why I think it's important to set our patients' expectations. When you prescribe, I would say to the patient, you may notice a symptom benefit, but the main reason for prescribing this, is to reduce your risk of exacerbations, so that's why we're going to keep you on the drug. Uh, likely for a year, in order to see whether we get that number down, uh, and that we've stabilized your condition.
Presenter
